Anavex Life Sciences Corp. AVXL
We take great care to ensure that the data presented and summarized in this overview for ANAVEX LIFE SCIENCES CORP. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AVXL
View all-
Black Rock Inc. New York, NY6.39MShares$51.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$41 Million0.0% of portfolio
-
State Street Corp Boston, MA2.95MShares$23.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.02MShares$16.2 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY973KShares$7.82 Million0.02% of portfolio
-
Nwam LLC Mercer Island, WA874KShares$7.02 Million0.58% of portfolio
-
Invesco Ltd. Atlanta, GA864KShares$6.94 Million0.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny823KShares$6.61 Million0.02% of portfolio
-
Northern Trust Corp Chicago, IL777KShares$6.24 Million0.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA710KShares$5.7 Million0.0% of portfolio
Latest Institutional Activity in AVXL
Top Purchases
Top Sells
About AVXL
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Insider Transactions at AVXL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 11
2025
|
Christopher U Missling President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
145,048
-8.76%
|
$1,305,432
$9.58 P/Share
|
|
Sep 11
2025
|
Christopher U Missling President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
187,500
+10.18%
|
$937,500
$5.04 P/Share
|
|
Jun 05
2025
|
Steffen Thomas Director |
SELL
Payment of exercise price or tax liability
|
Direct |
11,349
-20.63%
|
$79,443
$7.75 P/Share
|
|
Jun 05
2025
|
Steffen Thomas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+47.62%
|
$50,000
$1.76 P/Share
|
|
Mar 24
2025
|
Christopher U Missling President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
282,497
-16.14%
|
$2,542,473
$9.63 P/Share
|
|
Mar 24
2025
|
Christopher U Missling President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
500,000
+22.22%
|
$0
$0.92 P/Share
|
|
Jun 14
2024
|
Peter D.O. Donhauser Director |
BUY
Open market or private purchase
|
Direct |
2,835
+36.18%
|
$8,505
$3.64 P/Share
|
|
May 15
2024
|
Steffen Thomas Director |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$20,000
$4.52 P/Share
|
|
Mar 28
2024
|
Christopher U Missling President and CEO |
SELL
Open market or private sale
|
Direct |
73,380
-5.54%
|
$366,900
$5.11 P/Share
|
|
Mar 28
2024
|
Christopher U Missling President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
73,380
+5.25%
|
$73,380
$1.32 P/Share
|
|
Jun 29
2023
|
Christopher U Missling President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
232,000
+15.65%
|
$232,000
$1.6 P/Share
|
|
Jun 28
2023
|
Christopher U Missling President and CEO |
SELL
Open market or private sale
|
Direct |
268,000
-20.84%
|
$1,876,000
$7.98 P/Share
|
|
Jun 28
2023
|
Christopher U Missling President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
268,000
+17.24%
|
$268,000
$1.6 P/Share
|
|
May 25
2022
|
Athanasios Skarpelos Director |
SELL
Open market or private sale
|
Direct |
50,000
-3.69%
|
$450,000
$9.06 P/Share
|
|
May 25
2022
|
Athanasios Skarpelos Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+3.56%
|
$0
$0.92 P/Share
|
|
Jun 29
2021
|
Sandra Boenisch PFO & Treasurer |
SELL
Open market or private sale
|
Direct |
166,696
-87.89%
|
$4,334,096
$26.53 P/Share
|
|
Jun 29
2021
|
Sandra Boenisch PFO & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
166,696
+30.22%
|
$666,784
$4.96 P/Share
|
|
Jun 29
2021
|
Christopher U Missling President and CEO |
SELL
Open market or private sale
|
Direct |
51,620
-4.83%
|
$1,342,120
$26.0 P/Share
|
|
Jun 29
2021
|
Christopher U Missling President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
51,620
+4.6%
|
$51,620
$1.32 P/Share
|
|
May 21
2021
|
Elliot Favus Director |
SELL
Open market or private sale
|
Direct |
145,000
-100.0%
|
$1,595,000
$11.7 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 738K shares |
|---|
| Payment of exercise price or tax liability | 439K shares |
|---|